tiprankstipranks
Trending News
More News >
Advertisement

IDVO - ETF AI Analysis

Compare

Top Page

IDVO

Amplify International Enhanced Dividend Income ETF (IDVO)

Rating:69Neutral
Price Target:
IDVO’s rating suggests it is a solid, but not flawless, international dividend ETF, supported by strong holdings in high-quality companies like TSMC, Novartis, and AstraZeneca, which benefit from robust financial performance, innovation, and generally positive technical trends. Large positions in stable global banks such as Sumitomo Mitsui, Mitsubishi UFJ, Barclays, and Bank of Montreal also help, though some face cash flow, leverage, or macroeconomic challenges that slightly weigh on the fund. The main risk factor is its meaningful concentration in financial institutions, where issues like high leverage, loan losses, and economic uncertainty could impact overall returns.
Positive Factors
Strong Recent Performance
The ETF has shown strong gains over the past month, three months, and year-to-date, indicating solid recent momentum.
Healthy Top Holdings
Most of the largest positions, including major financial, technology, and healthcare names, have delivered positive year-to-date performance that supports the fund.
Broad Sector Diversification
Holdings spread across financials, materials, industrials, technology, energy, healthcare, and other sectors help reduce the impact of weakness in any single industry.
Negative Factors
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can modestly reduce net returns over time.
Heavy U.S. Exposure
Despite being an international-focused strategy, the portfolio is heavily tilted toward U.S. securities, limiting the benefits of global diversification.
Mixed Performance Among Top Holdings
While most top holdings are performing well, at least one significant position has been weak year-to-date, which can drag on overall results if that continues.

IDVO vs. SPDR S&P 500 ETF (SPY)

IDVO Summary

The Amplify International Enhanced Dividend Income ETF (IDVO) is an actively managed fund (no fixed index) that focuses on international companies paying attractive dividends. It holds a mix of sectors like financials, materials, and technology, with major positions in well-known names such as Alibaba, TSMC, Novartis, and AstraZeneca. Investors might consider IDVO to seek regular income from dividends while adding global diversification beyond the U.S. market. However, the fund’s value and income can go up and down with international markets and currency movements, and it is fairly concentrated in financial stocks.
How much will it cost me?The Amplify International Enhanced Dividend Income ETF (IDVO) has an expense ratio of 0.66%, which means you’ll pay $6.60 per year for every $1,000 invested. This is higher than average because the fund is actively managed, focusing on enhancing dividend income through a diversified global portfolio.
What would affect this ETF?The Amplify International Enhanced Dividend Income ETF (IDVO) could benefit from global economic growth, particularly in sectors like technology and financials, which are heavily weighted in its portfolio. However, it may face challenges from rising interest rates, which could impact dividend-paying stocks, and geopolitical tensions or regulatory changes in the international markets where it operates. Diversification across sectors and regions provides some resilience, but exposure to specific companies like Alibaba and TSMC means performance could be influenced by trends in e-commerce and semiconductor industries.

IDVO Top 10 Holdings

IDVO leans heavily on big international banks, with Japan’s Sumitomo Mitsui and Mitsubishi UFJ, plus Barclays and Bank of Montreal, acting as key engines and generally rising, giving the fund a solid financial backbone. Taiwan’s TSMC adds a tech-growth spark that’s also been climbing, while Novartis provides steady health care ballast. Alibaba has been more mixed, showing signs of life recently but still feeling past pressure, and AstraZeneca is losing a bit of steam. Overall, it’s a global ex-U.S. income play, tilted toward financials with a dash of tech and pharma.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Alibaba4.57%$40.07M$364.57B71.55%
68
Neutral
Novartis3.45%$30.26M$282.32B41.98%
80
Outperform
Sumitomo Mitsui3.27%$28.67M$135.77B41.06%
76
Outperform
TSMC3.27%$28.66M$1.46T57.92%
81
Outperform
Grupo Cibest3.08%$26.96M$20.82B106.45%
71
Outperform
Bank Of Montreal3.04%$26.66MC$131.41B37.47%
74
Outperform
Cameco2.94%$25.72MC$73.33B149.58%
71
Outperform
Siemens AG2.90%$25.44M$237.45B41.62%
78
Outperform
Mitsubishi UFJ2.84%$24.86M$202.27B43.14%
77
Outperform
Barclays2.83%$24.77M$91.88B82.22%
77
Outperform

IDVO Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
39.01
Positive
100DMA
37.82
Positive
200DMA
35.17
Positive
Market Momentum
MACD
1.06
Negative
RSI
64.40
Neutral
STOCH
64.52
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For IDVO, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 41.02, equal to the 50-day MA of 39.01, and equal to the 200-day MA of 35.17, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 64.40 is Neutral, neither overbought nor oversold. The STOCH value of 64.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDVO.

IDVO Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$888.04M0.65%
$933.41M0.85%
$775.96M0.59%
$500.80M0.55%
$280.98M0.66%
$266.48M0.60%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IDVO
Amplify International Enhanced Dividend Income ETF
41.87
12.85
44.28%
WCMI
First Trust WCM International Equity ETF
MFSI
MFS Active International ETF
OSEA
Harbor International Compounders ETF
DINT
Davis Select International Etf
QLTI
GMO International Quality ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement